85 – Sirt2 Regulates Intestinal Cell Proliferation and Differentiation

range: 31-35] (Table 1).Sedation was used in 4/47 (8.5%) procedures and 83% had biopsies.Anesthesia support was present in 2 cases (1 colonoscopy and 1 sigmoidoscopy) and obstetric monitoring was not used in any case.Median sigmoidoscopy scope insertion was 30 cm [range: 15 -40].There were no hospitalizations or pregnancy adverse events temporally associated with flexible sigmoidoscopy in either IBD or non-IBD patient groups.In 35/45 patients (77.8%), results of the flexible sigmoidoscopy resulted in addition of new therapies.In 42% of the IBD patients, there was a change in or initiation of biologic therapy.One intrauterine fetal demise between 30-34 weeks gestational age (GA) (procedure at 10 weeks GA) and one elective termination in second trimester (procedure at 13 weeks GA) occurred in the IBD group, but were not temporally or etiologically thought to be related to the sigmoidoscopy.Median GA at birth was 39 weeks in the IBD group [range: 37-41] and 40 weeks in the non-IBD group [range: 38-41].Rates of caesarean section delivery were 27.6% and 16.6% in IBD and non-IBD women, respectively (Table 2).CONCLUSION In this largest study to date of pregnant IBD patients undergoing flexible sigmoidoscopy, an unsedated, unprepped flexible sigmoidoscopy without obstetric monitoring was low risk and resulted in therapeutic change in 77.8%.There were no adverse events associated with the procedure regardless of trimester.